Gastroenterology

Gastroenterology

Volume 112, Issue 6, June 1997, Pages 1798-1810
Gastroenterology

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis

https://doi.org/10.1053/gast.1997.v112.pm9178669Get rights and content

Abstract

BACKGROUND & AIMS: Esophagitis healing proportions are often incorrectly called the healing rate. The aim of this study was to compare different drug classes by expressing the speed of healing and symptom relief through a new approach. METHODS: A fully recursive literature search to July 1996 identified 43 articles on gastroesophageal reflux disease (GERD) (7635 patients) meeting strict inclusion criteria: single- or double-blind randomized studies in adults with endoscopically proven erosive or ulcerative esophagitis. For each drug class, linear regression analysis estimated the average percentage of patients who were healed and heartburn free per week. RESULTS: Mean overall healing proportion irrespective of drug dose or treatment duration (< or =12 weeks) was highest with proton pump inhibitors (PPIs; 83.6% +/- 11.4%) vs. H2-receptor antagonists (H2RAs; 51.9% +/- 17.1%), sucralfate (39.2% +/- 22.4%), or placebo (28.2% +/- 15.6%). Correcting for patients without baseline heartburn, the mean heartburn-free proportion was highest with PPIs (77.4% +/- 10.4%) vs. H2RAs (47.6% +/- 15.5%). PPIs showed a significantly faster healing rate (11.7%/wk) vs. H2RAs (5.9%/wk) and placebo (2.9%/wk). PPIs provided faster, more complete heartburn relief (11.5%/wk) vs. H2RAs (6.4%/wk). CONCLUSIONS: More complete esophagitis healing and heartburn relief is observed with PPIs vs. H2RAs and occurs nearly twice as fast. This semiquantitative expression of speed of healing and symptom relief permits comparisons for future economic evaluation and quality-of-life assessments. (Gastroenterology 1997 Jun;112(6):1798-810)

References (0)

Cited by (825)

  • Gastroesophageal Reflux Disease

    2023, Primary Care - Clinics in Office Practice
  • Perception of Proton Pump Inhibitor Side Effects Among Members of the American Broncho-Esophagological Association

    2023, Journal of Voice
    Citation Excerpt :

    PPIs decrease gastric acid secretion by irreversibly inhibiting hydrogen-potassium ATPase in parietal cells. They have demonstrated efficacy in the management of GERD and its complications, in risk control of gastrointestinal bleeding and in the prevention of non-steroidal anti-inflammatory drug induced ulcers.2–4 Although initially thought to be free of significant side effects, several observational studies in the past decade have suggested an association between PPI use and concerning adverse events.

  • Gastroesophageal reflux disease (GERD)

    2023, Handbook of Gastrointestinal Motility and Disorders of Gut-Brain Interactions, Second Edition
View all citing articles on Scopus
View full text